⌘+K

Pulse Explore Communities Researchers Journals

Home Communities Explore

October 25, 2018European Respiratory JournalOpen Access

Compassionate use of delamanid in combination with bedaquiline for the treatment of multidrug-resistant tuberculosis

Jeffrey Hafkin Norbert Hittel Alexandra Martin Rajesh Gupta

View Full Paper

Ask AI

Bookmark

Share

Abstract

Updated data from the Otsuka compassionate use programme show that regimens combining delamanid and bedaquiline appear effective in MDR-TB cases with limited treatment optionshttp://ow.ly/zdE330mlkLN

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Hafkin et al. (2018) studied this question.

synapsesocial.com/papers/6a9a4d75352e687f024d5356 https://doi.org/10.1183/13993003.01154-2018

View Full Paper

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Early outcomes in MDR-TB and XDR-TB patients treated with delamanid under compassionate useReview · 2017 · 46 citations
2First case of extensively drug-resistant tuberculosis treated with both delamanid and bedaquilineOriginal Research · 2016 · 92 citations
3Cardiac safety of extensively drug-resistant tuberculosis regimens including bedaquiline, delamanid and clofazimineOriginal Research · 2016 · 32 citations
4Bedaquiline and Delamanid Combination Treatment of 5 Patients with Pulmonary Extensively Drug-Resistant TuberculosisOriginal Research · 2017 · 54 citations
5Safety and efficacy of exposure to bedaquiline−delamanid in multidrug-resistant tuberculosis: a case series from France and LatviaCase Report · 2018 · 36 citations

Bedaquiline and delamanid for the treatment of multidrug-resistant tuberculosis: a multicentre cohort study in Korea2018
Combined treatment of drug-resistant tuberculosis with bedaquiline and delamanid: a systematic review2018
Long-term mortality assessment of multidrug-resistant tuberculosis patients treated with delamanid2015
Muco-obstructive lung disease exhibits distinct hypoxic and inflammatory airway epithelial gene pathwaysEuropean Respiratory Journal · 2026
Don't discard the supernatant: pleural fluid cfDNA for molecular profiling in lung cancerEuropean Respiratory Journal · 2026

EMore from European Respiratory Journal

More from Otsuka (United States)

More from Pharmaceutical Product Development (United States)

More from Novel (Germany)

More from Otsuka (Germany)